Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer
Svend O. Freytag(Henry Ford Health System), Benjamin Movsas(Henry Ford Health System), Zhaoli Lane(Henry Ford Hospital), Jingfang Cheng(Henry Ford Health System), Farzan Siddiqui, Ron Rodriguez(Johns Hopkins University), Mohamed A. Elshaikh(Henry Ford Health System), Jan Pegg(Henry Ford Health System), Hans Stricker(University Hospital of Bern), Yingshu Zhang(Affiliated Zhongshan Hospital of Dalian University), Nancy Oja-Tebbe(Henry Ford Hospital), Renee Bourgeois(Henry Ford Health System), James O. Peabody(Henry Ford Hospital), Mei Lü(Ford Motor Company (United States)), Jae Ho Kim(Pusan National University Yangsan Hospital), Nilesh Gupta(Henry Ford Health System), I. Aref, Deepak Pradhan(New York University), Theodore L. DeWeese(Johns Hopkins University), Kenneth Levin(Henry Ford Health System), Kenneth Barton(Henry Ford Health System)
Cited by 86
Related Papers
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|776
Atorvastatin Induction of VEGF and BDNF Promotes Brain Plasticity after Stroke in Mice
|Journal of Cerebral Blood Flow & Metabolism|2005|449
The life and death of DNA-PK
|Oncogene|2004|407
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
|Clinical Cancer Research|2013|358